EGFR and non-small cell lung carcinoma: One of the earliest trials examining the role of neoadjuvant and perioperative TKI therapy in patients with EGFR + NSCLC was published in 2009, demonstrating a positive signal for gefitinib, with an ORR of 11% amongst the 36 study participants in this single-arm study [63].